Skip to content
Avastin(bevacizumab)
Alymsys, Avastin, Mvasi, Vegzelma, Zirabev (bevacizumab) is an antibody pharmaceutical. Bevacizumab was first approved as Lextemy on . It is used to treat colorectal neoplasms, fallopian tube neoplasms, glioblastoma, kidney neoplasms, and non-small-cell lung carcinoma amongst others in the USA. It has been approved in Europe to treat breast neoplasms, colorectal neoplasms, fallopian tube neoplasms, non-small-cell lung carcinoma, and ovarian neoplasms amongst others. The pharmaceutical is active against vascular endothelial growth factor A. In addition, it is known to target Vascular endothelial growth factor A.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
Trade Name
FDA
EMA
Alymsys, Avastin, Mvasi, Vegzelma, Zirabev
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Bevacizumab
Tradename
Proper name
Company
Number
Date
Products
AvastinbevacizumabGenentechN-125085 RX2004-02-26
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
alymsysBiologic Licensing Application2022-04-13
avastinBiologic Licensing Application2021-01-25
mvasiBiologic Licensing Application2019-06-25
vegzelmaBiologic Licensing Application2022-11-23
zirabevBiologic Licensing Application2021-02-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
colorectal neoplasms—D015179—
fallopian tube neoplasms—D005185—
glioblastomaEFO_0000515D005909—
kidney neoplasmsEFO_0003865D007680C64
non-small-cell lung carcinoma—D002289—
ovarian neoplasmsEFO_0003893D010051C56
peritoneal neoplasms—D010534—
uterine cervical neoplasms—D002583—
Agency Specific
FDA
EMA
Expiration
Code
bevacizumab, Avastin, Genentech, Inc.
2027-05-29Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FG: Vegf/vegfr (vascular endothelial growth factor) inhibitors
— L01FG01: Bevacizumab
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01L: Ocular vascular disorder agents
— S01LA: Antineovascularisation agents
— S01LA08: Bevacizumab
HCPCS
Code
Description
C9257
Injection, bevacizumab, 0.25 mg
J9035
Injection, bevacizumab, 10 mg
Q5107
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
Q5118
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg
Clinical
Clinical Trials
2264 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD0151796022482734372
Non-small-cell lung carcinomaD0022893512748213213
Breast neoplasmsD001943EFO_0003869C502112330514186
NeoplasmsD009369C808540637134
Ovarian neoplasmsD010051EFO_0003893C5627782524128
Liver neoplasmsD008113EFO_1001513C22.0265492888
Macular degenerationD008268EFO_0001365H35.3010272351875
Macular edemaD00826932428151575
Fallopian tube neoplasmsD0051851841151272
Stomach neoplasmsD013274EFO_0003897C1682111—28
Show 22 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlioblastomaD005909EFO_0000515449511—7137
Renal cell carcinomaD00229225459—1178
Lung neoplasmsD008175C34.9013456—664
Rectal neoplasmsD01200417367—356
Pancreatic neoplasmsD010190EFO_0003860C2523363—150
GliomaD005910EFO_000052014281—643
Brain neoplasmsD001932EFO_0003833C7112281—541
Colonic neoplasmsD003110C1810217—537
GliosarcomaD0183167291——33
Uterine cervical neoplasmsD0025835186—129
Show 72 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD008545929——235
Healthy volunteers/patients—211———22
SarcomaD012509812———19
Esophageal neoplasmsD004938C15414———18
Endometrial neoplasmsD016889EFO_0004230214———15
Triple negative breast neoplasmsD064726413———14
Head and neck neoplasmsD00625848———12
OligodendrogliomaD009837EFO_000063159———11
Central nervous system neoplasmsD01654339———11
CholangiocarcinomaD018281C22.137———10
Show 135 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CystadenocarcinomaD0035364————4
Hematologic neoplasmsD0193372————2
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.02————2
Myelomonocytic leukemia chronicD015477C93.12————2
ChondrosarcomaD0028132————2
PharmacokineticsD0105992————2
Pharyngeal neoplasmsD010610C14.02————2
HemangioblastomaD0183251———12
Von hippel-lindau diseaseD006623Q85.831———12
LymphedemaD008209Q82.02————2
Show 35 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
VitrectomyD014821————22
Diabetes complicationsD048909————22
HypertensionD006973EFO_0000537I10————22
Wound infectionD014946————11
Nerve tissue neoplasmsD009380————11
Retinal drusenD015593EFO_1001155————11
Intraocular pressureD007429————11
Molecular targeted therapyD058990————11
MyopiaD009216H52.1————11
Hereditary eye diseasesD015785————11
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBEVACIZUMAB
INNbevacizumab
Description
Bevacizumab, sold under the brand name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. For age-related macular degeneration it is given by injection into the eye.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)BEVACIZUMAB
Structure (InChI/SMILES or Protein Sequence)
>7V5N:A,E|bevacizumab fab light chain DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQP EDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >7V5N:B,F|bevacizumab fab heavy chain EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY LQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT
Identifiers
PDB6BFT, 7V5N
CAS-ID216974-75-3
RxCUI253337
ChEMBL IDCHEMBL1201583
ChEBI ID—
PubChem CID—
DrugBankDB00112
UNII ID2S9ZZM9Q9V (ChemIDplus, GSRS)
Target
Agency Approved
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
VEGF
NCBI Gene ID
7422
Protein name
vascular endothelial growth factor A
Protein synonyms
vascular endothelial growth factor A121, vascular endothelial growth factor A165, Vascular permeability factor, VPF
Uniprot ID
P15692
Mouse ortholog
Vegfa (22339)
vascular endothelial growth factor A (Q00731)
Alternate
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
NCBI Gene ID
—
Protein name
Vascular endothelial growth factor A
Protein synonyms
Vascular permeability factor
Uniprot ID
H0YBI8
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
Aybintio - Organon
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Zirabev - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Avastin - Roche
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 74,805 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details